Description:

SOUTHWEST ONCOLOGY GROUP S0226 FOLLOW UP FORM S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C32229DC-31B0-25D5-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C32229DC-31B0-25D5-E034-0003BA12F5E7

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00075764 Follow-Up - SOUTHWEST ONCOLOGY GROUP S0226 FOLLOW UP FORM - 2173463v3.0

No Instruction available.

  1. StudyEvent: SOUTHWEST ONCOLOGY GROUP S0226 FOLLOW UP FORM
    1. No Instruction available.
Header
Unnamed2
Vital Status
Vital Status
Disease Follow Up Status
Has the patient had a documented clinical assessment for this cancer since submission of the previous follow-up form?
Notice Of First Relapse Or Progression
Has the patient developed a first relapse or progression that has not been previously reported?
Notice Of New Primary
Has a new primary cancer or myelodysplastic syndrome (MDS) been diagnosed that has not been previously reported?
Non-protocol Treatment
Has the patient received any non-protocol cancer therapy not previously reported?
Long Term Toxicity
Has the patient experienced (prior to treatment for progression or relapse or a second primary, and prior to non-protocol treatment) any severe (grade >= 3) long term toxicity that has not been previously reported?
Comments
Ccrr Module For Southwest Oncology Group S0226 Follow Up Form